Drugs and Natural Products Used in COPD
Ahmet Karal
Hülya Celik
Agri Ibrahim Cecen University
PDF

Keywords

COPD
COPD drugs
Natural products

How to Cite

Karal, A., & Celik, H. (2022). Drugs and Natural Products Used in COPD. International Journal of Innovative Research and Reviews, 6(1), 51-58. Retrieved from http://www.injirr.com/article/view/88

Abstract

COPD, with its most general definition, is a disease represent by the formation of inflammation in the airways due to harmful particles and bronchoconstriction and irreversible enlargement and destruction of the lung sacs. Factors causing COPD include inhalation of tobacco or tobacco-like substances, environmental exposures, genetic factors, chemicals and air pollution. The drugs used in the treatment of COPD aim to reduce the breathing of patients, acute exacerbations and inflammation. While bronchodilator drugs, which are among the drugs used in treatment, prevent constriction, anti-inflammatory drugs act by reducing inflammation. It is also used in natural products such as ginger, mint and eucalyptus in the treatment of COPD. New methods are being improved for the treatment of COPD with the researches and studies conducted in recent years. In addition, new drugs are tried in treatment. More effective methods and drugs continue to be discovered for the treatment of COPD. Early diagnosis is of great importance in the treatment of COPD. Despite these, there is no cure for COPD.

PDF

References

E. Kalender, “KOAH Hastalarina Eczaci Tarafindan İlaç Eğitimi Verilmesinin Klinik Parametrelere ve Yaşam Kalitesine Etkisinin Değerlendirilmesi,” ANKARA ÜNİVERSİTESİ, 2013.
C. E. Mapp, P. Boschetto, P. Maestrelli, and L. M. Fabbri, “Occupational Asthma,” Am. J. Respir. Crit. Care Med., vol. 172, no. 3, pp. 280–305, Aug. 2005, doi: 10.1164/rccm.200311-1575SO.
“KOAH Nasıl Tedavi Edilir?,” (Türk Toraks Derneği, 2022. https://www.koahhastalaridernegi.org/.
O. Arseven, G. Öngen, B. Müsellim, and G. Okumuş, Türkiye’de Temel Akciğer Sağlığı Sorunları ve Çözüm Önerileri. 2010.
J. Vestbo et al., “Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary,” Am. J. Respir. Crit. Care Med., vol. 187, no. 4, pp. 347–365, 2013, doi: 10.1164/rccm.201204-0596PP.
S. Günay, M. Sariaydin, and N. Yilmaz Demırcı, “KOAH tedavisinde yeni bronkodilatörler ve kombinasyonları,” Tuberk. Toraks, vol. 64, no. 3, pp. 240–245, 2016, doi: 10.5578/tt.10267.
E. Tekin, M. Bayraktar, T. Sanalp Menekşe, and A. Bayramoğlu, “Treatment Management in Acute Exacerbation of COPD in the Emergency Department: Dilemma in Oxygen Therapy,” Int. J. Innov. Res. Rev., vol. 4, no. 2, pp. 23–29, 2020, [Online]. Available: http://www.injirr.com/article/view/64.
Khaled Almadhoun Sandeep Sharma., “Bronchodilators,” StatPearls[Internet], 2021, [Online]. Available: https://www.ncbi.nlm.nih.gov/books/NBK519028/.
B. G. Higgins, R. M. Powell, S. Cooper, and A. E. Tattersfield, “Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis,” Eur. Respir. J., vol. 4, no. 4, pp. 415–420, 1991.
“Salbutamol,” National Center for Biotechnology Information (2020). Pub-Chem Compound Summary for CID 2083,. https://pubchem.ncbi.nlm.nih.gov/compound/Salbutamol.
D. Morgan, J. Paull, B. Richmond, E. Wilson‐Evered, and S. Ziccone, “Pharmacokinetics of intravenous and oral salbutamol and its sulphate conjugate.,” Br. J. Clin. Pharmacol., vol. 22, no. 5, pp. 587–593, 1986, doi: 10.1111/j.1365-2125.1986.tb02939.x.
“Fenoterol in Turkish—,” Fenoterol in Türkiye, 2022. https://www.ilaçlar.net/medicine-tr/fenoterol.
“Levalbuterol,” National Library of Medicine National Center for Biotechnology InformationPubChem CID 123600. https://pubchem.ncbi.nlm.nih.gov/compound/Levalbuterol.
“Levalbuterol CONCENTRATE Vial For Nebulizer - Uses, Side Effects, and More,” WebMD. (n.d.). 2020. https://www.webmd.com/drugs/2/drug-17082-1390/levalbuterol-hcl-inhalation/levalbuterol-concentrated-solution-inhalation/details.
C. Riether et al., “Stimulation of β2-adrenergic receptors inhibits calcineurin activity in CD4+ T cells via PKA-AKAP interaction,” Brain. Behav. Immun., vol. 25, no. 1, pp. 59–66, 2011, doi: 10.1016/j.bbi.2010.07.248.
. A. Cooperberg, S. M. Breckenridge, A. M. Arbelaez, and P. E. Cryer, “Terbutaline and the Prevention of Nocturnal Hypoglycemia in Type 1 Diabetes,” 2008, doi: 10.2337/dc08-0520.
J. J. Salomon et al., “Beta-2 Adrenergic Agonists Are Substrates and Inhibitors of Human Organic Cation Transporter 1,” Mol. Pharm., vol. 12, no. 8, pp. 2633–2641, 2015, doi: 10.1021/mp500854e.
G. Anderson, “Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2-adrenoceptor agonist bronchodilator,” Life Sci. Vol. 52, Issue 26, 1993, Pages 2145-2160, doi: 10.1016/0024-3205(93)90729-M.
J. F. Donohue et al., “Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: A one year evaluation of safety and tolerance,” Ther. Adv. Respir. Dis., vol. 2, no. 2, pp. 37–48, 2008, doi: 10.1177/1753465808089455.
N. A. Hanania et al., “The safety and efficacy of arformoterol and formoterol in COPD,” COPD J. Chronic Obstr. Pulm. Dis., vol. 7, no. 1, pp. 17–31, 2010, doi: 10.3109/15412550903499498.
E. Naline, A. Trifilieff, R. A. Fairhurst, C. Advenier, and M. Molimard, “Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi,” Eur. Respir. J., vol. 29, no. 3, pp. 575–581, 2007, doi: 10.1183/09031936.00032806.
L. P. and C. R. Mark Kagan, Jeremy Dain, “Metabolism and Pharmacokinetics of Indacaterol in Humans,” Drug Metab. Dispos. Sept., vol. 40, no. 9, pp. 1712–1722, 2012, doi: 10.1124/dmd.112.046151.
A. Koch et al., “International Journal of COPD Dovepress Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat ® versus placebo and formoterol twice daily in patients with gOlD 2-4 COPD: results from two replicate 48-week studies,” 2014, doi: 10.2147/COPD.S62502.
E. D. Deeks, “Olodaterol: A review of its use in chronic obstructive pulmonary disease,” Drugs, vol. 75, no. 6, pp. 665–673, 2015, doi: 10.1007/s40265-015-0371-4.
M. Cazzola, R. Testi, and M. G. Matera, “of Salmeterol,” Drug Dispos., vol. 41, no. 1, pp. 19–30, 2002.
N. J. Gross, “Anticholinergic agents in asthma and COPD,” Eur. J. Pharmacol., vol. 533, no. 1–3, pp. 36–39, 2006, doi: 10.1016/j.ejphar.2005.12.072.
P. J. Barnes, “"The role of anticholinergics in chronic obstructive pulmonary disease,” Am. J. Med. Suppl., vol. 117, no. 12, pp. 24–32, 2004, doi: https://doi.org/10.1016/j.amjmed.2004.10.018.
K. J. Rehder, “Adjunct therapies for refractory status asthmaticus in children,” Respir. Care, vol. 62, no. 6, pp. 849–865, 2017, doi: 10.4187/respcare.05174.
“Ipratropium Bromide (Code C29128),” NCI Metathesaurus. https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C29128.
“Ipratropium,” DrugBank Online. https://go.drugbank.com/drugs/DB00332.
“Oxitropium bromide,” Wikipedia., 2022. https://en.wikipedia.org/wiki/Oxitropium_bromide.
C. Frith, P. A., Jenner, B., Dangerfield, R., Atkinson, J., & Drennan, “Oxitropium bromide: dose-response and time-response study of a new anticholinergic bronchodilator drug.,” Chest, vol. 89, no. 2, pp. 249-253., 1986, doi: https://doi.org/10.1378/chest.89.2.249.
and M. G. M. Cazzola, Mario, Clive P. Page, “Aclidinium bromide for the treatment of chronic obstructive pulmonary disease,” Expert Opin. Pharmacother., vol. 14, no. 9, pp. 1205–1214, 2013.
“Aclidinium,” İn LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK548832/.
“Glycopyrronium,” DrugBank. https://go.drugbank.com/drugs/DB00986.
“Tiotropium Bromide (Code C84608),” NCI Metathesaurus. CL449040 (see NCI Metathesaurus info).
F. Price, D., Sharma, A., & Cerasoli, “Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients,” Expert Opin. Drug Metab. Toxicol., vol. 5, no. 4, pp. 417-424., 2009, doi: https://doi.org/10.1517/17425250902828337.
M. Decramer et al., “Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients,” Respir. Physiol. Neurobiol., vol. 185, no. 2, 2013, doi: 10.1016/j.resp.2012.08.022.
A. İlvan, “Kronik Obstrüktif Akci¤er Hastal›¤› Alevlenmesinde Farmakolojik Tedavi,” Solunum Derg., vol. 0, no. 324, pp. 14–17, 2009, [Online]. Available: https://jag.journalagent.com/eurasianjpulmonol/pdfs/SOLUNUM_11_SUP_3_14_17.pdf.
R. A. Incalzi, A. Gemma, C. Marra, R. Muzzolon, O. Capparella, and P. Carbonin, “Chronic obstructive pulmonary disease: An original model of cognitive decline,” Am. Rev. Respir. Dis., vol. 148, no. 2, pp. 418–424, 1993, doi: 10.1164/ajrccm/148.2.418.
“Theophylline (Code C872),” NCI Metathesaurus. C0039771 (see NCI Metathesaurus info).
“Aminophylline,” National Library of Medicine National Center for Biotechnology Information, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Aminophylline.
“Antienflamatuvar,” https://tr.wikipedia.org/static/images/mobile/copyright/wikipedia-wordmark-tr.svg, 2022. https://tr.wikipedia.org/wiki/Antiinflamatuar.
J. V. and D. S. Stelios Loukides, Konstantinos Bartziokas, “Novel Anti-Inflammatory Agents in COPD: Targeting Lung and Systemic Inflammation,” vol. 14, no. 2, pp. 235–245, 2013, doi: 10.2174/1389450111314020008.
M. Cazzola, C. P. Page, L. Calzetta, and M. G. Matera, “Emerging anti-inflammatory strategies for COPD,” Eur. Respir. J., vol. 40, no. 3, pp. 724–741, 2012, doi: 10.1183/09031936.00213711.
L. SEZER, Murat; KART, “KOAH tedavisinde inhale kortikosteroidler. Güncel Göğüs Hastalıkları Serisi,” vol. 1, no. 1, pp. 24-30., 2013, [Online]. Available: http://ghs.asyod.org/Dosyalar/GHS/2013/1/c4df9be6-8b78-496f-b384-e899e68e54a6.pdf.
P. J. Barnes, “Anti-inflammatory actions of glucocorticoids: molecular mechanisms,” Clin. Sci., vol. 94, no. 6, pp. 557–572, doi: https://doi.org/10.1042/cs0940557.
M. D. for the F. I. Jadwiga A. Wedzicha, M.D., Donald Banerji, M.D., Kenneth R. Chapman, M.D., Jørgen Vestbo, M.D., D.M.Sc., Nicolas Roche, M.D., R. Timothy Ayers, M.Sc., Chau Thach, Ph.D., Robert Fogel, M.D., Francesco Patalano, M.D., and Claus F. Vogelmeier, “Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD,” N Engl J Med, vol. 374, pp. 2222–2234, 2016, doi: DOI: 10.1056/NEJMoa1516385.
“Fluticasone,” National Institutes of Health National Library of Medicine National Center for Biotechnology Information, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Fluticasone.
A. Roth, G., Wikby, A., Nilsson, L., & Thalén, “High-performance liquid chromatographic determination of epimers, impurities, and content of the glucocorticoid budesonide and preparation of primary standard.,” J. Pharm. Sci., vol. 69, no. 7, pp. 766–770, 1980, doi: 10.1002/jps.2600690705.
“Budesonide,” National Institutes of Health National Library of Medicine National Center for Biotechnology Information, 2022. https://pubchem.ncbi.nlm.nih.gov/compound/Budesonide.
“Prednisolone for COPD,” COPD NEWS TODAY, 2022. https://copdnewstoday.com/prednisolone-for-copd/.
K. F. Rabe, “Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease,” Br. J. Pharmacol., vol. 163, no. 1, pp. 53–67, 2011, doi: 10.1111/j.1476-5381.2011.01218.x.
P. M. Calverley, K. F. Rabe, U. M. Goehring, S. Kristiansen, L. M. Fabbri, and F. J. Martinez, “Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials,” Lancet, vol. 374, no. 9691, pp. 685–694, 2009, doi: 10.1016/S0140-6736(09)61255-1.
“Roflumilast,” DRUKBANK Online. https://go.drugbank.com/drugs/DB01656.
“Cilomilast,” DrugBank online. https://go.drugbank.com/drugs/DB03849.
“Antibiyotik Nedir ?,” Türkiye İlaç ve Tıbbi Cihaz Kurumu Akılcı İlaç Kullanımı Dairesi, 2022. http://www.akilciilac.gov.tr/?page_id=1009.
and L. Ç. Sayıner, A., M. Polatlı, “Türk Toraks Derneği akut bronşit ve KOAH ve bronşektazi alevlenmelerinde antibiyotik tedavisi uzlaşı raporu,” Türk Toraks Derg., vol. 10, no. 7, pp. 3–7, 2009, [Online]. Available: https://turkthoracj.org/content/files/sayilar/147/buyuk/pdf_Toraksder_637.pdf.
M. Bakır, “Günümüzde KOAH Akut Alevlenmelerinde Antibiyotik Seçimi,” vol. 8, no. 1, pp. 40–50, 2003, [Online]. Available: http://www.floradergisi.org/managete/fu_folder/2003-01/2003-8-1-040-050.pdf.
P. Ball, “Epidemiology and treatment of chronic bronchitis and its exacerbations,” Chest, vol. 108, no. 2 SUPPL., pp. 43S-52S, 1995, doi: 10.1378/chest.108.2_Supplement.43S.
“KOAH Nasıl Tedavi Edilir,” Türk Toraks Derneği,. https://www.koahhastalaridernegi.org/menu/52/koah-nasil-tedavi-edilir.
“Erdosteine,” DrugBank. https://go.drugbank.com/drugs/DB05057.
A. M. Sadowska, J. Verbraecken, K. Darquennes, and W. De Backer, “The role for N-acetylcysteine in the management of COPD.,” Int. J. Chron. Obstruct. Pulmon. Dis., vol. 1, no. 2, pp. 425–434, 2006, doi: 10.2147/copd.2006.1.2.99.
H. Worth, C. Schacher, and U. Dethlefsen, “Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: A placebo-controlled double-blind trial,” Respir. Res., vol. 10, pp. 1–7, 2009, doi: 10.1186/1465-9921-10-69.
V. P. D. Bastos et al., “Inhaled 1,8-cineole reduces inflammatory parameters in airways of ovalbumin-challenged guinea pigs,” Basic Clin. Pharmacol. Toxicol., vol. 108, no. 1, pp. 34–39, 2011, doi: 10.1111/j.1742-7843.2010.00622.x.
A. Çifci et al., “Ginger (Zingiber officinale) prevents severe damage to the lungs due to hyperoxia and inflammation,” Turkish J. Med. Sci., vol. 48, no. 4, pp. 892–900, 2018, doi: 10.3906/sag-1803-223.
R. J. GREEN, Natural therapies for emphysema and COPD: relief and healing for chronic pulmonary disorders. Inner Traditions/Bear & Co, 2007.
Diane L. McKay* and Jeffrey B., “IA Review of the Bioactivity and Potential Health Benefits of Peppermint Tea (Mentha piperita L.),” Phyther. Res., vol. 20, pp. 619–633, 2006, doi: 10.1002/ptr.1936.
F. Scaglione, K. Weiser, and M. Alessandria, “Effects of the standardised ginseng extract G115® in patients with chronic bronchitis: A nonblinded, randomised, comparative pilot study,” Clin. Drug Investig., vol. 21, no. 1, pp. 41–45, 2001, doi: 10.2165/00044011-200121010-00006.
S. K. Eo, Y. S. Kim, C. K. Lee, and S. S. Han, “Antiviral activities of various water and methanol soluble substances isolated from Ganoderma lucidum,” J. Ethnopharmacol., vol. 68, no. 1–3, pp. 129–136, 1999, doi: 10.1016/S0378-8741(99)00067-7.
F. Isbaniah, W. H. Wiyono, F. Yunus, A. Setiawati, U. Totzke, and M. A. Verbruggen, “Echinacea purpurea along with zinc, selenium and vitamin C to alleviate exacerbations of chronic obstructive pulmonary disease: Results from a randomized controlled trial,” J. Clin. Pharm. Ther., vol. 36, no. 5, pp. 568–576, 2011, doi: 10.1111/j.1365-2710.2010.01212.x.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The authors keep the copyrights of the published materials with them, but the authors are aggee to give an exclusive license to the publisher that transfers all publishing and commercial exploitation rights to the publisher. The puslisher then shares the content published in this journal under CC BY-NC-ND license.